Article information
Full text is only aviable in PDF
Bibliografía
[1.]
A. Timpe, E.H. Runyon.
The relationship of “atypical” acid-fast bacteria to human disease. A preliminary report.
J Lab Clin Med, 44 (1954), pp. 202-209
[2.]
E. Wolinsky.
Mycobacterial diseases other than tuberculosis.
Clin Infect Dis, 15 (1992), pp. 1-10
[3.]
K. Wickman.
Clinical significance of nontuberculous mycobacteria: a bacteriological survey o Swedish strains isolated between 1973 and 1981.
Scand J Infect Dis, 18 (1986), pp. 337-345
[4.]
D.R. Hoover, A.J. Saah, H. Bacellar, et al.
Clinical manifestations of AIDS in the era of pneumocystis profilaxis Multicenter AIDS Co- hort Study.
N Engl J Med, 329 (1993), pp. 1.922-1.926
[5.]
D.P. Chin, P.C. Hopewell.
Mycobacterial complications of HIV infection.
Clin Chest Med, 17 (1996), pp. 697-711
[6.]
American Thoracic Society.
Diagnosis and treatment of disease caused by nontuberculous micobacteria.
Am Rev Respir Dis, 156 (1997), pp. 1-25
[7.]
T.E. Hartman, S.J. Swensen, D.E. Williams.
Mycobacterium avium intracellulare complex: evaluation with CT.
Radiology, 187 (1993), pp. 23-26
[8.]
L. Heifets.
MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs.
Antimicrob Agents Chemoter, 32 (1988), pp. 1.131-1.136
[9.]
C.H. Ahn, R.J. Wallace Jr., L.C. Steele, D.T. Murphy.
Sulfonamide containing regimens for disease caused by rifampin -resistant Mycobacterium kansasii.
Am Rev Respir Dis, 135 (1987), pp. 10-16
[10.]
J.R. Wallace Jr., D. Dunbar, B.A. Brown, G. Onyi, R. Dunlap, C.H. Ahn, et al.
Rifampin-resistant Mycobacterium kansasii.
Clin Infect Dis, 18 (1994), pp. 736-743
[11.]
L.S. Young, L. Wiviott, M. Wu, et al.
Azitromycin for treatment on Mycobacterium intracellulare complex infection in patients with AIDS.
Lancet, 338 (1991), pp. 1.107-1.109
[12.]
B.C. Dautzenberg, T.S. Legris, et al.
Activity of clarithromycin against Mycobacterium avium infection in patients with acquired immune deficiency syndrome.
Am Rev Respir Dis, 144 (1991), pp. 564-569
[13.]
C.L. Woodley, J.O. Kilburn.
In vitro susceptibility of Mycobacterium avium complex and M. tuberculosis strains to a spiro-pipe- ridyl rifamycina.
Am Rev Respir Dis, 126 (1982), pp. 586-587
[14.]
M. Jerome, R. Johnson, R.E. Johnson.
Mycobacterium avium complex pulmonary disease.
Am Rev Respir Dis, 143 (1991), pp. 1.381-1.385
[15.]
R.J. Wallace Jr., B.A. Brown, D.E. Griffith, W.M. Girard, D.T. Murphy.
Clarithromycina regimens for pulmonary Mycobacterium avium complex: the first 50 patients.
Am J Respir Crit Care Med, 153 (1996), pp. 1.766-1.772
[16.]
B. Dautzenberg, D. Piperno, P. Diot, J. Truffot C-Pernot, P. Chauvin, The Clarithromycina Study Group of France.
Clarithromycina in the treatment of Mycobacterium avium lung infections in patients without AIDS.
Chest, 107 (1995), pp. 1.035-1.040
[17.]
American Thoracic Society.
Diagnosis and treatment of disease caused by nontuberculous mycobacteria.
Am Rev Respir Dis, 142 (1990), pp. 940-953
[18.]
B. Dautzenberg, T. Saint Marc, M.C. Mehoyas, et al.
Clarithromycin an other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome.
Arch Intern Med, 153 (1993), pp. 368-372
[19.]
M. Pomerantz, L. Madsen, M. Goble, M. Iseman.
Surgical manage- ment of resistant mycobacterial tuberculosis and other mycobacte- rial pulmonary infections.
Ann Thorac Surg, 52 (1991), pp. 1.108-1.112
[20.]
J. Chiu, J. Nussbaum, S. Bozzette, J. Tilles, L.S. Young, J. Leedom, et al.
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacina, ethambutol, rifampin and cipro- floxacin.
Ann Intern Med, 113 (1990), pp. 358-361
[21.]
S.D. Shafran, J. Singer, D.P. Zarowny, P. Philips, I. Salit, S.L. Walmsley, et al.
A comparison of two regimens for the treatment of Mycobacterium avium complex bacteriemia AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine and ciprofloxacin.
N Engl J Med, 335 (1996), pp. 377-383
[22.]
Centers for Disease Control.
Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.
MMWR, 45 (1996), pp. 921-925
[23.]
M. Pierce, S. Crampton, D. Herny, L. Heifits, A. LaMarca, et al.
A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with ad- vanced acquired immunodeficiency syndrome.
N Engl J Med, 335 (1996), pp. 384-391
[24.]
D.V. Havlir, M.P. Dube, F.R. Sattler, D.N. Forthal, C.A. Kemper, M.W. Dunne, et al.
Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both.
N Engl J Med, 335 (1996), pp. 392-398
[25.]
H. Masur.
Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus.
N Engl J Med, 329 (1993), pp. 898-904
[26.]
W. Pezzia, J.W. Raleigh, M.C. Bailey, E.A. Toth, J. Silverblatt.
Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin.
Rev Infect Dis, 3 (1981), pp. 1.035-1.039
[27.]
C.H. Ahn, J.R. Lowell, S.S. Ahn, S.I. Ahn, G.A. Hurst.
Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii.
Am Rev Respir Dis, 128 (1983), pp. 1.048-1.050
[28.]
G.D. Harris, W.G. Johanson Jr., D.P. Nicholson.
Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii.
Am Rev Respir Dis, 112 (1975), pp. 31-36
[29.]
P.A. Jenkins, J. Banks, I.A. Campbell, A.P. Smith.
Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol.
Thorax, 49 (1994), pp. 442-445
[30.]
J. Sauret, S. Hernández Flix, E. Castro, L. Hernández, V. Ausina, P. Coll.
Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months’ chemotherapy.
Tuber Lung Dis, 76 (1995), pp. 104-108
[31.]
C.H. Ahn, R.J. Wallace Jr., L.C. Steele, D.T. Murphy.
Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii.
Am Rev Respir Dis, 135 (1987), pp. 10-16
[32.]
J.M. Swenson, R.J. Wallace Jr., V.A. Silcox, C. Thomsberry.
Antimicrobial susceptibility testing of 5 subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.
Antimicrob Agents Che- mother, 28 (1985), pp. 807-811
[33.]
B.A. Brown, R.J. Wallace Jr., G.O. Onyi, V. De Rosa, R.J. Wallace.
III. Activities of four macrolides, including clarithromycina, against Mycobacterium fortuitum. Mycobacterium chelonae-like organisms.
Antimicrob Agents Chemoter, 36 (1992), pp. 180-184
[34.]
H. Edelstein.
Mycobacterium marinum skin infections.
Arch Intern Med, 154 (1994), pp. 1.359-1.364
[35.]
J. Banks, P.A. Jenkins, A.P. Smith.
Pulmonary infection with Mycobacterium maulmoense: a review of treatment and response.
Tuberle, 66 (1985), pp. 197-203
[36.]
R.C. Bell, J.H. Higuchi, W.N. Donovan, I. Drasnow, W.G. Johanson.
Mycobacterium simiae: clinical features and follow up of twenty four patients.
Am Rev Respir Dis, 127 (1983), pp. 35-38
Copyright © 1999. Sociedad Española de Neumología y Cirugía Torácica
